Although the vaccination approach involving p19Arf + IFNβ gene transfer provided evidence for an effective antitumor immune response, we also wished to explore whether in situ cancer gene therapy using our vectors can serve as immunotherapy. This evidence concerns the gene IFNB1 and cancer.